55 related articles for article (PubMed ID: 1581636)
1. Analysis of the active conformation of angiotensin II: a comparison of AII and non-peptide AII antagonists.
Pierson ME; Freer RJ
Pept Res; 1992; 5(2):102-5. PubMed ID: 1581636
[TBL] [Abstract][Full Text] [Related]
2. An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations.
Mavromoustakos T; Kolocouris A; Zervou M; Roumelioti P; Matsoukas J; Weisemann R
J Med Chem; 1999 May; 42(10):1714-22. PubMed ID: 10346924
[TBL] [Abstract][Full Text] [Related]
3. Novel angiotensin II antagonists distinguish amphibian from mammalian angiotensin II receptors expressed in Xenopus laevis oocytes.
Ji H; Sandberg K; Catt KJ
Mol Pharmacol; 1991 Feb; 39(2):120-3. PubMed ID: 1996080
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753.
Wong PC; Timmermans PB
J Pharmacol Exp Ther; 1991 Jul; 258(1):49-57. PubMed ID: 2072311
[TBL] [Abstract][Full Text] [Related]
5. Proposals for the angiotensin II receptor-bound conformation by comparative computer modeling of AII and cyclic analogs.
Joseph MP; Maigret B; Scheraga HA
Int J Pept Protein Res; 1995 Dec; 46(6):514-26. PubMed ID: 8748712
[TBL] [Abstract][Full Text] [Related]
6. Biological and conformational evaluation of angiotensin II lactam bridge containing analogues.
Oliveira VX; Fázio MA; Silva AF; Campana PT; Pesquero JB; Santos EL; Costa-Neto CM; Miranda A
Regul Pept; 2011 Dec; 172(1-3):1-7. PubMed ID: 21787808
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem.
Nikiforovich GV; Marshall GR
Biochem Biophys Res Commun; 1993 Aug; 195(1):222-8. PubMed ID: 8363604
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II receptor subtypes and biological responses in the adrenal cortex and medulla.
Balla T; Baukal AJ; Eng S; Catt KJ
Mol Pharmacol; 1991 Sep; 40(3):401-6. PubMed ID: 1654513
[TBL] [Abstract][Full Text] [Related]
9. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
Yanagisawa H; Amemiya Y; Kanazaki T; Shimoji Y; Fujimoto K; Kitahara Y; Sada T; Mizuno M; Ikeda M; Miyamoto S; Furukawa Y; Koike H
J Med Chem; 1996 Jan; 39(1):323-38. PubMed ID: 8568823
[TBL] [Abstract][Full Text] [Related]
10. N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans.
Huskey SE; Miller RR; Chiu SH
Drug Metab Dispos; 1993; 21(5):792-9. PubMed ID: 7902238
[TBL] [Abstract][Full Text] [Related]
11. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):719-25. PubMed ID: 2179531
[TBL] [Abstract][Full Text] [Related]
12. Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DUP 753 and PD 121981, in rabbit heart.
Scott AL; Chang RS; Lotti VJ; Siegl PK
J Pharmacol Exp Ther; 1992 Jun; 261(3):931-5. PubMed ID: 1602398
[TBL] [Abstract][Full Text] [Related]
13. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.
Zhang WJ; Nikiforovich GV; Pérodin J; Richard DE; Escher E; Marshall GR
J Med Chem; 1996 Jul; 39(14):2738-44. PubMed ID: 8709104
[TBL] [Abstract][Full Text] [Related]
14. Design of biologically active, conformationally constrained GnRH antagonists.
Struthers RS; Tanaka G; Koerber SC; Solmajer T; Baniak EL; Gierasch LM; Vale W; Rivier J; Hagler AT
Proteins; 1990; 8(4):295-304. PubMed ID: 2091022
[TBL] [Abstract][Full Text] [Related]
15. Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Feb; 252(2):726-32. PubMed ID: 2179532
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of various proposed models of the receptor-bound conformation of H-Tyr-Tic-Phe-OH related delta-opioid antagonists.
Wilkes BC; Schiller PW
Biopolymers; 1995; 37(6):391-400. PubMed ID: 8589244
[TBL] [Abstract][Full Text] [Related]
17. Antisense-designed peptides: a comparative study focusing on possible complements to angiotensin II.
Holsworth DD; Kiely JS; Root-Bernstein RS; Overhiser RW
Pept Res; 1994; 7(4):185-93. PubMed ID: 7718050
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II vs its type I antagonists: conformational requirements for receptor binding assessed from NMR spectroscopic and receptor docking experiments.
Wilkes BC; Masaro L; Schiller PW; Carpenter KA
J Med Chem; 2002 Sep; 45(20):4410-8. PubMed ID: 12238921
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional structure of an angiotensin II-Fab complex at 3 A: hormone recognition by an anti-idiotypic antibody.
Garcia KC; Ronco PM; Verroust PJ; Brünger AT; Amzel LM
Science; 1992 Jul; 257(5069):502-7. PubMed ID: 1636085
[TBL] [Abstract][Full Text] [Related]
20. On the molecular basis of the recognition of angiotensin II (AII). NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131.
Tzakos AG; Bonvin AM; Troganis A; Cordopatis P; Amzel ML; Gerothanassis IP; van Nuland NA
Eur J Biochem; 2003 Mar; 270(5):849-60. PubMed ID: 12603318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
